Liaison Technologies Positioned to Accelerate Growth in Health Information Business

Plans to expand focus on life sciences, healthcare and health information exchanges for integration and data harmonization of patient information

ATLANTA--(BUSINESS WIRE)-- Liaison Technologies, a global provider of cloud-based integration and data management services and solutions, announced today that the company has closed a round of financing that provides up to $30 million in additional funding to significantly accelerate its growth in the life sciences, healthcare and health information exchange (HIE) markets. Liaison currently provides business integration and secure data management services across a range of industries and within healthcare to hospitals, health plans, medical device companies and pharmaceutical companies.

“Our goal is to facilitate improved patient care and beneficial use from the increasing amount of available health information by leveraging our proven platform for connecting and harmonizing health information data sources. This investment will help us reach that goal,” said Bruce Chen, executive vice president Healthcare Informatics and CTO of Liaison Technologies. “Our expertise in complex data management and integration enables us to bring a unique offering to the health information market that will have a compelling impact across the healthcare industry.”

Liaison’s industry leading cloud-based integration and data harmonization solutions help companies in many industries reduce costs and increase business efficiencies. By applying these same services to the healthcare and life sciences industries, Liaison can help enterprises quickly move past simple compliance initiatives and gain value from data to provide better long-term patient care and to speed up the secondary use of information among pharmaceutical, healthcare and HIE organizations.

“This investment validates Liaison’s achievements in, and vision for, the healthcare industry. With over 600 healthcare and life sciences customers today accounting for over 30 percent of our total business, this investment will accelerate our customer growth and market presence on a greater scale,” said Bob Renner, CEO of Liaison Technologies. “Given Liaison’s solidly profitable current business, we are excited about the ability to deploy this new invested capital to accelerate our growth and continue to give healthcare organizations an innovative and unique approach to address health information integration and harmonization needs.”

About Liaison Technologies

Liaison Technologies is a global integration and data management services company providing unique and high-value services to securely move, transform and manage business information in the cloud. With a comprehensive array of business-to-business and application-to-application integration and data transformation services, Liaison’s practitioners implement data management infrastructures adapted to specific business requirements within the life sciences and healthcare industries. Headquartered in Atlanta, Liaison has offices in the Netherlands, Finland, Sweden and the United Kingdom. For more information, visit www.liaison.com.

Liaison and the Liaison logo are trademarks of Liaison Technologies, Inc. All other names or product names mentioned in this release are trademarks or registered trademarks of their respective companies.



CONTACT:

Carabiner Communications
Dana Cogan, 770-441-7921
[email protected]

KEYWORDS:   United States  North America  Georgia

INDUSTRY KEYWORDS:   Technology  Data Management  Networks  Security  Health  Hospitals  General Health

MEDIA:

Logo
 Logo

Report

Driving Engagement in an Evolving Healthcare Ecosystem

Deep-dive into evolving consumer expectations in healthcare today and how leading providers are shaping their infrastructure to connect with patients through virtual care.

Suggested Articles

UPMC Health Plan is expanding its medication adherence program with Sempre Health to include diabetes medications.

Despite efforts to improve patient safety over the past 20 years, results have not been optimal. We raise vital questions and renewed areas of focus.

The Trump administration has enlisted CVS Health to pilot administering the therapy to patients in long-term care facilities and at home.